EGFR and non-small cell lung carcinoma: One is an open-label randomized phase II study compared the combination of erlotinib and bevacizumab versus erlotinib alone in patients with non-squamous NSCLC harboring EGFR mutations in first-line setting.[40] The addition of bevacizumab to erlotinib conferred a significant improvement in PFS.